NASDAQ:ARWR News 8 December 2025 - 7 January 2026

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is seeing a sharp pullback in Tuesday trading (Dec. 16, 2025), with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76. That drop may look dramatic in isolation, but it’s landing on top of an unusually eventful stretch for the RNA interference (RNAi) biotech: Arrowhead just transitioned into a commercial-stage story after its first FDA approval, picked up an FDA Breakthrough Therapy designation for a follow-on indication, and kicked off a new Alzheimer’s-related clinical program—three ingredients that tend to increase both upside narratives and day-to-day volatility

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2 As of intraday trading on December 9, 2025, Arrowhead Pharmaceuticals stock trades around $69 per share, giving the company a market value in the $9–9.5 billion range. That’s up dramatically from under $10 per share at its 52‑week low, and represents a